Osimertinib After Definitive Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC: Subsequent Treatments and PPO From the Phase III LAURA Study

Mustafa Özgüroğlu, Myung-Ju Ahn, Xiaorong Dong, James Chih-Hsin Yang, Satoshi Oizumi, Koichi Goto, Manuel Cobo, Sang-We Kim, Te-Chun Hsia, Jarin Chindaprasirt, Fernanda Fujiki, Natalia Valdiviezo, Ignacio Casarini, Terufumi Kato, Xiangning Huang, Azura Evans, Elena Armenteros-Monterroso, Ana Bolanos, Suresh S. Ramalingam, Shun Lu

Open source

DOI: 10.1158/1078-0432.ccr-25-4523
Published: 2026-09-09
Container: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/1078-0432.ccr-25-4523,
  title = {Osimertinib After Definitive Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC: Subsequent Treatments and PPO From the Phase III LAURA Study},
  author = {Mustafa Özgüroğlu and Myung-Ju Ahn and Xiaorong Dong and James Chih-Hsin Yang and Satoshi Oizumi and Koichi Goto and Manuel Cobo and Sang-We Kim and Te-Chun Hsia and Jarin Chindaprasirt and Fernanda Fujiki and Natalia Valdiviezo and Ignacio Casarini and Terufumi Kato and Xiangning Huang and Azura Evans and Elena Armenteros-Monterroso and Ana Bolanos and Suresh S. Ramalingam and Shun Lu},
  year = {2026},
  journal = {Clinical Cancer Research},
  doi = {10.1158/1078-0432.ccr-25-4523},
  url = {https://doi.org/10.1158/1078-0432.ccr-25-4523}
}

RIS

TY  - JOUR
TI  - Osimertinib After Definitive Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC: Subsequent Treatments and PPO From the Phase III LAURA Study
AU  - Mustafa Özgüroğlu
AU  - Myung-Ju Ahn
AU  - Xiaorong Dong
AU  - James Chih-Hsin Yang
AU  - Satoshi Oizumi
AU  - Koichi Goto
AU  - Manuel Cobo
AU  - Sang-We Kim
AU  - Te-Chun Hsia
AU  - Jarin Chindaprasirt
AU  - Fernanda Fujiki
AU  - Natalia Valdiviezo
AU  - Ignacio Casarini
AU  - Terufumi Kato
AU  - Xiangning Huang
AU  - Azura Evans
AU  - Elena Armenteros-Monterroso
AU  - Ana Bolanos
AU  - Suresh S. Ramalingam
AU  - Shun Lu
PY  - 2026
JO  - Clinical Cancer Research
DO  - 10.1158/1078-0432.ccr-25-4523
UR  - https://doi.org/10.1158/1078-0432.ccr-25-4523
ER  -

APA

Özgüroğlu, M., Ahn, M., Dong, X., Yang, J. C., Oizumi, S., Goto, K., Cobo, M., Kim, S., Hsia, T., Chindaprasirt, J., Fujiki, F., Valdiviezo, N., Casarini, I., Kato, T., Huang, X., Evans, A., Armenteros-Monterroso, E., Bolanos, A., Ramalingam, S. S., & Lu, S. (2026). Osimertinib After Definitive Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC: Subsequent Treatments and PPO From the Phase III LAURA Study. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-25-4523

Source records

crossref · retrieved 2026-09-26T05:34:19.901Z